Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes
Status:
Unknown status
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to evaluate the
efficacy and safety of SP2086 as monotherapy in patients with Type 2 Diabetes Mellitus in
Metformin monotherapy Who Have Inadequate Glycemic Control treated with diet and exercise for
3 months